DBV Technologies S.A.
NASDAQ:DBVTBiotechnology
-$0.16 today
- Market cap
- $238.98M
- Beta
- -0.22
- P/E (TTM)
- -8.3
- EPS (TTM)
- -$0.39
Volume 0.17M
Average 0.24M
DBVT Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
DBV Technologies S.A.NASDAQ: DBVT
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization grows, but more slowly than its trailing trend
Q1 FY2026 depreciation & amortization of $2M rose 26.7% year over year, behind the +53.3% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 37.6% from the prior quarter. Over 3 fiscal years it compounded at -27.5% a year.
Context
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +26.7% toward the trailing-twelve-month pace of +53.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 7.73M USD
- Year-over-year change
- +13.5%
- 4-year CAGR
- -2.0%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.73M | +13.5% |
| FY2024 | 2024-12-31 | 6.81M | -48.2% |
| FY2023 | 2023-12-31 | 13.16M | -35.2% |
| FY2022 | 2022-12-31 | 20.3M | +142.3% |
| FY2021 | 2021-12-31 | 8.38M | — |
Depreciation & Amortization vs competitors
How DBVT compares with its peers on the latest reported figures
- DBVT's LTM Mar 2026 depreciation & amortization of $12.36M is the 2nd highest of the 11 companies compared; the peer median is $1.4M.
- Its year-over-year change of +53.3% is the 2nd highest of 10, against a peer median of +0.0%.
- Over three fiscal years its annual growth of -27.5% compares with a peer median of +13.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $19.68M | -2.6% | +2.9% | 28.9% | |
| LTM Mar 2026 | $12.36M | +53.3% | -27.5% | — | |
| LTM Mar 2026 | $3.44M | -15.5% | +19.5% | 89.4% | |
| LTM Mar 2026 | $3.06M | +36.2% | +7.2% | — | |
| LTM Mar 2026 | $2.93M | -1.6% | -0.7% | 1.4% | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $2.12M | +4.8% | +22.0% | — |
ENGNenGene Holdings Inc. | LTM Apr 2026 | $670K | +79.6% | +28.8% | — |
| LTM Mar 2026 | $605K | +5.0% | +24.6% | — | |
| LTM Mar 2026 | $326K | +0.0% | +3.2% | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $325.5K | — | +443.4% | — |
| LTM Mar 2026 | $106K | -33.8% | -39.0% | 294.4% | |
| Peer median (excluding DBVT) | $1.4M | +0.0% | +13.3% | 59.2% | |
Competitors are the stored peer set for DBVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 5.71M | 4.8M | 15.73M | 0 | 0 |
| Cost of Revenue | 9.27M | 20.3M | 0 | 6.81M | 17.67M |
| Gross Profit | (3.57M) | (15.5M) | 15.73M | (6.81M) | (17.67M) |
| Gross Margin | -62.5% | -322.9% | 100.0% | — | — |
| Research & Development | 70.34M | 75.5M | 60.22M | 89.9M | 116.68M |
| Selling, General & Admin | 23.83M | 17.56M | 31.94M | 23.81M | 28.28M |
| Operating Expenses | 93.93M | 101.48M | 92.16M | 113.71M | 147.06M |
| Depreciation & Amortization | 8.38M | 20.3M | 13.16M | 6.81M | 7.73M |
| EBITDA | (91.16M) | (76.68M) | (63.27M) | (110.99M) | (139.32M) |
| EBITDA Margin | -1597.0% | -1597.5% | -402.3% | — | — |
| Operating Income | (98.61M) | (96.63M) | (76.43M) | (120.53M) | (147.06M) |
| Operating Margin | -1727.6% | -2013.1% | -486.0% | — | — |
| Interest Income | 521K | 406.29K | 3.71M | 2.73M | 601.86K |
| Interest Expense | 690K | 427K | 0 | 0 | 0 |
| Other Income / Expenses | 424K | 427K | 3.71M | 2.73M | 600K |
| Income Before Tax | (98.19M) | (96.2M) | (72.72M) | (117.8M) | (146.46M) |
| Pre-Tax Margin | -1720.2% | -2004.3% | -462.4% | — | — |
| Income Tax Expense | (381K) | 70K | 7K | (4.08M) | 491K |
| Net Income | (97.81M) | (96.3M) | (72.73M) | (113.72M) | (146.95M) |
| Net Margin | -1713.5% | -2006.3% | -462.4% | — | — |
| EPS (Basic) | (1.80) | (1.25) | (0.75) | (1.20) | (1.70) |
| EPS (Diluted) | (1.80) | (1.25) | (0.75) | (1.20) | (1.70) |
| Weighted Avg Shares | 55.1M | 77.38M | 95.12M | 96.17M | 86.4M |
| Weighted Avg Shares (Diluted) | 55.1M | 77.38M | 95.12M | 96.17M | 86.4M |
DBV Technologies S.A.
NASDAQ:DBVT
Intrinsic Alpha fair value
Locked
Current Price
$9.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.